

## Deutsch

DGAP Ad-hoc-Service

Tel: +49 (0)89 444 430 050 Fax: +49 (0)89 210298-72 Email: [newsroom@dgap.de](mailto:newsroom@dgap.de)

Meldende Gesellschaft:  
Aladdin Healthcare Technologies SE

ISIN:  
DE000A12ULL2

Ansprechpartner:  
Aladdin Healthcare Technologies SE  
Wade Smith  
Tel.: 030 700140449  
Fax:

Meldebeauftragter:  
Aladdin Healthcare Technologies SE  
Wade Smith  
Tel.: 030 700140449  
Fax:

E-Mail Ansprechpartner:  
E-Mail Meldebeauftragter:

[info@aladdinid.com](mailto:info@aladdinid.com)  
[info@aladdinid.com](mailto:info@aladdinid.com)

Börsenplätze: Regulierter Markt in Düsseldorf

DGAP-Ad-hoc: Aladdin Healthcare Technologies SE / Schlagwort(e): Verkauf  
Aladdin Healthcare Technologies SE meldet den Verkauf von Software und Intellectual Property (IP)

18.05.2021 CET/CEST

Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch DGAP - ein Service der EQS Group AG.  
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Aladdin Healthcare Technologies SE meldet den Verkauf von Software und Intellectual Property (IP)

BERLIN/LONDON, 18. Mai 2021 - Aladdin Healthcare Technologies SE (das "Unternehmen") gibt bekannt, dass seine 100%ige Tochtergesellschaft Aladdin Healthcare Technologies Ltd ("Aladdin Ltd") heute den Verkauf von spezifischer Software und Intellectual Property (IP) an einen Kunden mit Sitz in der Volksrepublik China abgeschlossen hat. Als Gegenleistung für den Verkauf hat der Kunde 500.000 GBP an Aladdin Ltd gezahlt.

Aladdin Ltd hat verschiedene KI-gesteuerte Technologieprodukte für den Gesundheitsmarkt entwickelt und entwickelt diese weiter. Sie hat den Prototyp einer KI-gesteuerten Drug Discovery Plattform und eines Knowledge Graph entwickelt, die auf verschiedene Bereiche der Arzneimittelentwicklung angepasst werden können. Bei der verkauften Software handelt es sich um das oben beschriebene Intellectual Property (IP), das jedoch speziell für die Entdeckung von niedermolekularen Medikamenten im Bereich Alzheimer und Demenz eingesetzt werden soll. Aladdin behält sich die Rechte vor, die Software in anderen Bereichen zu nutzen.

Wade Menpes-Smith

Kontakt:  
Aladdin Healthcare Technologies SE  
Unter den Linden 10  
10117 Berlin  
Tel 030 7700 140 449  
E-Mail: [info@aladdinid.com](mailto:info@aladdinid.com)  
[www.aladdinid.com](http://www.aladdinid.com)

Ende der Ad-hoc-Mitteilung

18.05.2021 CET/CEST Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.  
Medienarchiv unter <http://www.dgap.de>

Sprache: Deutsch  
Unternehmen: Aladdin Healthcare Technologies SE  
Unter den Linden 10  
10117 Berlin  
Deutschland  
Telefon: 030 700140449  
E-Mail: info@aladdinid.com  
Internet: www.aladdinid.com  
ISIN: DE000A12ULL2  
WKN: A12ULL  
Börsen: Regulierter Markt in Düsseldorf  
EQS News ID: 1197804

Ende der Mitteilung

DGAP News-Service

1197804 18.05.2021 CET/CEST

English

DGAP Ad-hoc-Service

Tel: +49 (0)89 444 430 050 Fax: +49 (0)89 210298-72 Email: newsroom@dgap.de

Issuer:  
Aladdin Healthcare Technologies SE

ISIN:  
DE000A12ULL2

Contact:  
Aladdin Healthcare Technologies SE  
Wade Smith  
Phone: 030 700140449  
Fax:

Agent:  
Aladdin Healthcare Technologies SE  
Wade Smith  
Phone: 030 700140449  
Fax:

E-mail Contact: info@aladdinid.com  
E-mail Agent: info@aladdinid.com

Listings: Regulated Market in Dusseldorf

DGAP-Ad-hoc: Aladdin Healthcare Technologies SE / Key word(s): Disposal  
Aladdin Healthcare Technologies SE reports the sale of software and intellectual property

18-May-2021 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014,  
transmitted by DGAP - a service of EQS Group AG.  
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies SE reports the sale of software and intellectual property

BERLIN/LONDON, 18 May 2021 - Aladdin Healthcare Technologies SE (the "Company") reports that its 100% subsidiary Aladdin Healthcare Technologies Ltd ("Aladdin Ltd") has today completed the sale of specific software and intellectual property to a customer based in the People's Republic of China. As consideration for the sale, the customer has paid GBP 500,000 to Aladdin Ltd.

Aladdin Ltd has developed and is developing various AI-driven technology products for the healthcare market. It has developed prototype AI-driven Drug Discovery Platform and Knowledge Graph which can be tailored to various areas of drug development. The software being sold is the above-described intellectual property but specifically to be used for small molecule drug discovery in the area of Alzheimer's and Dementia. Aladdin retains the rights to use it in other areas.

Wade Menpes-Smith

Contact:  
Aladdin Healthcare Technologies SE  
Unter den Linden 10

10117 Berlin  
Tel 030 7700 140 449  
email: info@aladdinid.com  
www.aladdinid.com

End of ad hoc announcement

18-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  
Archive at [www.dgap.de](http://www.dgap.de)

Language: English  
Company: Aladdin Healthcare Technologies SE  
Unter den Linden 10  
10117 Berlin  
Germany  
Phone: 030 700140449  
E-mail: info@aladdinid.com  
Internet: www.aladdinid.com  
ISIN: DE000A12ULL2  
WKN: A12ULL  
Listed: Regulated Market in Dusseldorf  
EQS News ID: 1197804

End of Announcement

DGAP News Service

1197804 18-May-2021 CET/CEST

Message for BaFin:

Time of the decision to delay the publication of this news:  
08-March-2021 11:00 CET/CEST

Aladdin Healthcare Technologies SE  
with its registered office in Berlin, Germany  
Commercial Register of the Local Court of Charlottenburg under no. HRB 173762 B  
(the 'Company')

MINUTES OF A RESOLUTION OF THE ADMINISTRATIVE BOARD  
DATED 8<sup>th</sup> March 2021 REGARDING  
THE DELAY OF DISCLOSURE OF INSIDE INFORMATION PURSUANT TO ART. 17 PARA. 4 MARKET  
ABUSE REGULATION

The following directors of the Administrative Board (the 'Directors' and each a 'Director') of the Company were present or duly represented at this meeting (the 'Meeting') of the Administrative Board of the Company (the 'Board'):

Present:

- Wade Menpes-Smith, Director, Chairman of the Administrative Board, joining by way of conference call;
- Bimal Shah, Director, joining by way of conference call;
- Hamish Badenoch joining by way of conference call.

#### OPENING OF THE MEETING

The Meeting was opened at 10 a.m and all the members of the Board being present or represented declared that they waive adherence to form and time requirements pursuant to statutory law and the Company's articles of association and adopted by way of an adoption of resolutions via telephone call pursuant to Sec. 9 (2) of the Articles of Association. All members of Administrative Board participated in the resolution and no member of the Administrative Board

has objected such procedure.

## REPORTS AND DELIBERATIONS

The Chairman reported that the Company's 100% subsidiary Aladdin Healthcare Technologies Ltd ('Aladdin Ltd') will today sign a sale of software and intellectual property rights to a technology company based in China. Aladdin Ltd has developed prototype AI driven Drug Discovery Platform and Knowledge Graph which can be tailored to various areas of drug development. The software being sold is the above described intellectual property but specifically to be used for small molecule drug discovery in the area of Alzheimer's and Dementia. Due to the uncertain nature of performing business in China and negative experience with reliability of Chinese business partners, the Board has made the decision not to transfer the intellectual property until the date that Aladdin Ltd receives the funds as per the sale agreement. The Company also therefore believes that the transaction will not be completed until Aladdin is in receipt of the funds and has transferred the intellectual property.

It was also reported that the Company continues to be able to ensure confidentiality of all information relating to the sale agreement. Only such persons are aware of the information they need to carry out their duties and who are obliged to maintain confidentiality. This applies both to the Company's employees and to external consultants engaged by the Company. In addition, the counter party is already bound to secrecy by the NDA.

The Board determined due to the amount being received by Aladdin Ltd in the sale, that potentially it could qualify as inside information pursuant to Art. 7 MAR as it might have a significant effect on the price of the shares of the Company. The significant sale of intellectual property could have, if publicly known, a significant impact on the price on the Company's shares on the Stock Exchange. In particular, the Board assesses that it is more likely than not that Aladdin Ltd will be able to execute the transaction, if it receives the sale amount from the buyer.

The Board discussed to make use of the possibility outlined in Art. 17 para. 4 MAR and delay the publication of these circumstances by way of an ad-hoc notification as due to the uncertain nature of doing business in China the sale cannot be considered complete until the funds have been received by Aladdin Ltd and the intellectual property and software has been transferred to the buyer. An immediate publication of the signing of the sale might cause disadvantages to the Company, as the capital markets might deem this transaction already highly likely although the Company has experienced in the past a high degree of uncertainty and unreliability with Chinese business partners despite signed contracts. Therefore, the Company is of the opinion that a immediate release will jeopardize the interest of the Company and that the interest to keep the information confidential until the purchase price is received outweighs the interest of the capital market for immediate information. In particular, the Company might face pressure from the Chinese customer to re-negotiate the transaction to collect the purchase price, if the transaction was already announced prior to receiving the monies.

Each Director of the Company, after careful review of the current status of the discussions on the sale of the software and related information, deems the forthcoming of the transaction to be in the best interests and for the corporate benefit of the Company and within the corporate object of the Company and confirms that he/she does not have any conflict of interest pertaining to the below resolutions.

Each of the Directors also declares that, to the best of his/her knowledge, the matters referred to in the present minutes are in compliance with the Articles and the applicable legal provisions and do not breach any agreement to which the Company is a party to or by which the Company is bound.

## RESOLUTIONS

After having carefully considered and discussed the above, the Board therefore UNANIMOUSLY RESOLVES:

1. It noted the current status of the Transaction.
2. It assesses the facts outlined above to potentially qualify as inside information within the meaning of Art. 7 MAR, in particular the signing of the Transaction agreement.
3. To delay the disclosure of the inside information on the current status of the Transaction in accordance with Art. 17 para. 4 MAR as any disclosure might be to advanced as the Transaction has not been fully completed. The Board of Directors refers in this regard to the ESMA Guidelines on legitimate interests of issuers to delay the disclosure of inside information dated 20 October 2016, in particular to Note 8 a.

4. To approve and authorize, the publication of the Ad-Hoc Notice immediately after the Transaction is completed. For the avoidance of doubt, the Transaction will be considered complete when the buyer has transferred the full sales price to Aladdin Ltd and Aladdin Ltd has transferred the Intellectual Property and related Software.

5. To examine the present situation continuously and regularly with regard to all new facts occurring and the degree of probability of occurrence and the considerable potential for influencing the share price that may result from such new developments. The Administrative Board will also review the question of the continued existence of the grounds for exemption pursuant to Art. 17 para. 4 MAR, reassess them if necessary and document its decision on an ongoing basis.

The following persons were involved in the adoption of this resolution:

Name	Telephone number	Business address
Wade Menpes-Smith	+44 7714 719696	Epworth House, 25 City Road, London, EC1Y 1AA
Bimal Shah	+44 7747 075724	Epworth House, 25 City Road, London, EC1Y 1AA
Hamish Badenoch	+44 7900 326568	Epworth House, 25 City Road, London, EC1Y 1AA

There being no further items on the agenda and no one present demanding to speak, the meeting concluded at 11 a.m.

London, 08 March 2021

SIGNED:

---

Name: Wade Menpes-Smith, Chairman